HomeTagsSupplemental

Supplemental

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva

JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics